Vischer with investors Forbion & Sanofi on financing round
Vischer advised Forbion and Sanofi Ventures on all legal issues related to their role as lead investors in Granite Bio USD 70m Series B financing round.
The context
Headquartered in Basel, Granite Bio is a clinical-stage immunology company which specialises in the development of antibodies targeting the root causes of different inflammatory, autoimmune and fibrotic conditions.
The company raised a combined USD 100m in funding between a USD 30m Series A financing round led by founding investors Versant Ventures and Novartis Venture Fund, and a USD 70m Series B financing round led by Forbion, a venture capital firm with offices in The Netherlands, Germany and USA, and Sanofi Ventures, the corporate venture capital arm of Sanofi.
The Vischer team
The Vischer corporate/M&A team featured partner Christian Wyss (pictured), managing associate Luzius Zumstein, senior associate Pauline Pfirter and associate Alessandro L. Meyer.
